PE20211653A1 - Metodos para tratar cancer - Google Patents
Metodos para tratar cancerInfo
- Publication number
- PE20211653A1 PE20211653A1 PE2020001785A PE2020001785A PE20211653A1 PE 20211653 A1 PE20211653 A1 PE 20211653A1 PE 2020001785 A PE2020001785 A PE 2020001785A PE 2020001785 A PE2020001785 A PE 2020001785A PE 20211653 A1 PE20211653 A1 PE 20211653A1
- Authority
- PE
- Peru
- Prior art keywords
- formula
- mdm2
- mpn
- compound
- compounds
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 abstract 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 abstract 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 abstract 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 abstract 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 abstract 2
- 208000017733 acquired polycythemia vera Diseases 0.000 abstract 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 abstract 2
- 208000037244 polycythemia vera Diseases 0.000 abstract 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 230000033616 DNA repair Effects 0.000 abstract 1
- 229940083338 MDM2 inhibitor Drugs 0.000 abstract 1
- 239000012819 MDM2-Inhibitor Substances 0.000 abstract 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 abstract 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000025084 cell cycle arrest Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 206010028537 myelofibrosis Diseases 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 208000003476 primary myelofibrosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009758 senescence Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a un inhibidor de homologo de minuto 2 doble de raton (MDM2) tal como un compuesto de Formula (I) o Formula (II) o una sal farmaceuticamente aceptable del mismo, el compuesto de Formula (I) o Formula (II) se encuentra en forma cristalina o amorfa; tambien se refiere a metodos para tratar un neoplasma mieloproliferativo (MPN) que comprende el paso de administrar una cantidad terapeuticamente efectiva del inhibidor de MDM2 de Formula (I) o Formula (II). Los compuestos de la invencion son utiles en el tratamiento de distintos tipos de cancer tales como: un neoplasma mieloproliferativo (MPN), que incluye policitemia vera (PV), trombocitemia esencial (ET) y mielofibrosis primaria; leucemia mielogenosa cronica (CML); carcinoma de celulas de Merkel (MCC); entre otros. Los compuestos Formula (I) o Formula (II) actuan sobre la oncoproteina MDM2 neutralizando su interaccion con p53, el cual es un supresor de tumores implicado en la detencion del ciclo celular, apoptosis, senescencia y reparacion de ADN.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664673P | 2018-04-30 | 2018-04-30 | |
| US201862701088P | 2018-07-20 | 2018-07-20 | |
| US201862781942P | 2018-12-19 | 2018-12-19 | |
| US201962834848P | 2019-04-16 | 2019-04-16 | |
| PCT/US2019/029906 WO2019213074A1 (en) | 2018-04-30 | 2019-04-30 | Methods of treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211653A1 true PE20211653A1 (es) | 2021-08-24 |
Family
ID=68386769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001785A PE20211653A1 (es) | 2018-04-30 | 2019-04-30 | Metodos para tratar cancer |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12115153B2 (es) |
| EP (1) | EP3787625A4 (es) |
| JP (2) | JP2021523220A (es) |
| KR (1) | KR20210019422A (es) |
| CN (1) | CN112512525A (es) |
| AU (1) | AU2019263064A1 (es) |
| BR (1) | BR112020022148A2 (es) |
| CA (1) | CA3098606A1 (es) |
| CL (1) | CL2020002833A1 (es) |
| CO (1) | CO2020014599A2 (es) |
| CR (1) | CR20200576A (es) |
| IL (2) | IL278345B2 (es) |
| JO (1) | JOP20200273A1 (es) |
| MX (2) | MX2020011608A (es) |
| PE (1) | PE20211653A1 (es) |
| PH (1) | PH12020551820A1 (es) |
| SG (1) | SG11202010793UA (es) |
| TN (1) | TN2020000210A1 (es) |
| TW (2) | TW202146387A (es) |
| WO (1) | WO2019213074A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114450008A (zh) * | 2019-09-16 | 2022-05-06 | 诺华股份有限公司 | Mdm2抑制剂用于治疗骨髓纤维化的用途 |
| TW202128156A (zh) * | 2019-11-14 | 2021-08-01 | 美商夸格智財控股有限公司 | 用於癌症治療之btk抑制劑及mdm2抑制劑之組合 |
| WO2021175192A1 (en) * | 2020-03-02 | 2021-09-10 | Ascentage Pharma (Suzhou) Co., Ltd. | Treatment methods and biomarkers for mdm2 inhibitors |
| WO2022219128A1 (en) * | 2021-04-15 | 2022-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | In vitro tests allowing to identify the potential for mdm2 inhibitors to induce the selection of mutations in patients suffering from a myeloproliferative neoplasm |
| WO2023039160A1 (en) * | 2021-09-09 | 2023-03-16 | Kartos Therapeutics | Methods of treating a cancer overexpressing one or more bcl-2 family proteins |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| MA38193B1 (fr) * | 2012-12-07 | 2018-12-31 | Geron Corp | Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives |
| MX368703B (es) | 2013-02-28 | 2019-10-11 | Amgen Inc | Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer. |
| JOP20200296A1 (ar) * | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| MA39094B1 (fr) * | 2013-11-11 | 2020-06-30 | Amgen Inc | Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers |
| AU2014354769A1 (en) * | 2013-11-26 | 2016-05-26 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| AU2014372167A1 (en) * | 2013-12-23 | 2016-06-09 | Novartis Ag | Pharmaceutical combinations |
| RU2716256C2 (ru) | 2014-01-28 | 2020-03-11 | Бак Инститьют Фо Ресеч Он Эйджинг | Способы и композиции для уничтожения стареющих клеток и для лечения заболеваний и расстройств, ассоциированных со старением |
| TW201613576A (en) * | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
-
2019
- 2019-04-30 IL IL278345A patent/IL278345B2/en unknown
- 2019-04-30 SG SG11202010793UA patent/SG11202010793UA/en unknown
- 2019-04-30 KR KR1020207034245A patent/KR20210019422A/ko not_active Application Discontinuation
- 2019-04-30 TW TW110132121A patent/TW202146387A/zh unknown
- 2019-04-30 CN CN201980043405.4A patent/CN112512525A/zh active Pending
- 2019-04-30 AU AU2019263064A patent/AU2019263064A1/en active Pending
- 2019-04-30 TN TNP/2020/000210A patent/TN2020000210A1/en unknown
- 2019-04-30 JO JOP/2020/0273A patent/JOP20200273A1/ar unknown
- 2019-04-30 WO PCT/US2019/029906 patent/WO2019213074A1/en unknown
- 2019-04-30 US US17/052,040 patent/US12115153B2/en active Active
- 2019-04-30 BR BR112020022148-1A patent/BR112020022148A2/pt unknown
- 2019-04-30 CA CA3098606A patent/CA3098606A1/en active Pending
- 2019-04-30 MX MX2020011608A patent/MX2020011608A/es unknown
- 2019-04-30 CR CR20200576A patent/CR20200576A/es unknown
- 2019-04-30 PE PE2020001785A patent/PE20211653A1/es unknown
- 2019-04-30 JP JP2021510264A patent/JP2021523220A/ja active Pending
- 2019-04-30 TW TW108115047A patent/TWI741286B/zh active
- 2019-04-30 IL IL308399A patent/IL308399A/en unknown
- 2019-04-30 EP EP19796292.1A patent/EP3787625A4/en active Pending
-
2020
- 2020-10-30 PH PH12020551820A patent/PH12020551820A1/en unknown
- 2020-10-30 MX MX2024003655A patent/MX2024003655A/es unknown
- 2020-10-30 CL CL2020002833A patent/CL2020002833A1/es unknown
- 2020-11-25 CO CONC2020/0014599A patent/CO2020014599A2/es unknown
-
2024
- 2024-01-24 JP JP2024008582A patent/JP2024050668A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2020002833A1 (es) | 2021-04-30 |
| CR20200576A (es) | 2021-04-30 |
| CO2020014599A2 (es) | 2021-02-26 |
| JOP20200273A1 (ar) | 2020-11-01 |
| IL308399A (en) | 2024-01-01 |
| TWI741286B (zh) | 2021-10-01 |
| AU2019263064A1 (en) | 2020-12-03 |
| TW202146387A (zh) | 2021-12-16 |
| BR112020022148A2 (pt) | 2021-04-13 |
| CA3098606A1 (en) | 2019-11-07 |
| PH12020551820A1 (en) | 2021-07-26 |
| IL278345A (es) | 2020-12-31 |
| KR20210019422A (ko) | 2021-02-22 |
| JP2024050668A (ja) | 2024-04-10 |
| US20210186946A1 (en) | 2021-06-24 |
| IL278345B1 (en) | 2024-01-01 |
| EP3787625A4 (en) | 2022-01-26 |
| US12115153B2 (en) | 2024-10-15 |
| SG11202010793UA (en) | 2020-11-27 |
| WO2019213074A1 (en) | 2019-11-07 |
| EP3787625A1 (en) | 2021-03-10 |
| JP2021523220A (ja) | 2021-09-02 |
| IL278345B2 (en) | 2024-05-01 |
| TN2020000210A1 (en) | 2022-07-01 |
| MX2020011608A (es) | 2021-02-17 |
| CN112512525A (zh) | 2021-03-16 |
| TW201945340A (zh) | 2019-12-01 |
| MX2024003655A (es) | 2024-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211653A1 (es) | Metodos para tratar cancer | |
| UY36207A (es) | Inhibidores de la syk | |
| PE20171241A1 (es) | Terapias de combinacion para el tratamiento de canceres | |
| DOP2019000201A (es) | Compuestos inhibidores del vih | |
| CY1123595T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 | |
| CO2022016377A2 (es) | Inhibidores de kras tricíclicos fusionados | |
| CO2017000399A2 (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos | |
| CL2019002150A1 (es) | Derivados de 3-fenil-4-amino-imidazo[4,5-c]piridin-2-ona y 7-fenil-6-amino-purin-8-ona sustituidos, inhibidores de tirosinacinasas, en particular tirosinacinasa de bruton (btk); composiciones que contiene los compuestos; y uso para enfermedades tales como cáncer, autoinmunitarias, inflamatorias y tromboembólicas. (divisional solicitud 201703073) | |
| UY37926A (es) | Formulaciones de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo | |
| DOP2019000168A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| ECSP17047153A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| AR108202A1 (es) | Reducción de la carga tumoral minimal mediante la administración de antagonistas de ccr1 en combinación con inhibidores de pd-1 o inhibidores pd-l1 | |
| DOP2016000208A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| UY35353A (es) | Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| DOP2019000140A (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
| AR103110A1 (es) | Métodos de combinación para el tratamiento de cánceres | |
| EA201890812A1 (ru) | Дополнительная терапия 25-гидроксивитамином d и изделия для этого | |
| EA201790332A1 (ru) | Дополнительная терапия 25-гидроксивитамином d | |
| EA201691342A1 (ru) | Пиразолоновые соединения и их применение | |
| ECSP24009853A (es) | Compuestos tricíclicos como inhibidores de kras | |
| EA201892726A1 (ru) | Дейтерированный палбоциклиб | |
| EA201991412A1 (ru) | Ингибиторы поли(адф-рибоза)полимеразы (parp) |